Empagliflozin Mechanism of Action and Side Effects in CKD Patients
Empagliflozin is an SGLT2 inhibitor that blocks glucose reabsorption in the proximal tubule, reducing intraglomerular pressure through hemodynamic effects, and is recommended for CKD patients with eGFR ≥20 mL/min/1.73 m² despite manageable side effects including genital infections, volume depletion, and diabetic ketoacidosis risk. 1
Mechanism of Action
Empagliflozin inhibits sodium-glucose co-transporter 2 (SGLT2), the predominant transporter responsible for reabsorbing filtered glucose from the glomerular filtrate back into circulation 2. By blocking SGLT2 in the proximal tubule, empagliflozin:
- Increases urinary glucose excretion (approximately 64-78 grams per day), lowering the renal threshold for glucose 2
- Reduces intraglomerular pressure through restoration of tubuloglomerular feedback, causing initial reversible eGFR decline but long-term kidney protection 3, 4
- Decreases renal blood flow by approximately 6% in diabetic CKD patients through combined preglomerular and postglomerular effects without increasing renal vascular resistance 4
- Reduces hypoxia-induced angiogenic factors (VEGF, ANGPTL2) that contribute to diabetic kidney disease progression 5
The initial eGFR drop (approximately 3-4 mL/min/1.73 m² in first 4 weeks) is hemodynamic and reversible, representing reduced hyperfiltration rather than kidney injury 3. During chronic treatment, eGFR stabilizes with minimal annual decline (+0.23 mL/min/1.73 m²/year) compared to placebo (-1.46 mL/min/1.73 m²/year) 3.
Side Effects in CKD Patients
Common and Manageable Side Effects
Genital mycotic infections (6% vs 1% placebo):
- Higher risk in women than men 1
- Counsel patients on genital hygiene practices 1
- Most infections are easily treated; rare severe cases (Fournier gangrene) reported 1
Volume depletion:
- Monitor for hypovolemia, especially at treatment initiation 1
- Consider proactive diuretic dose reduction in high-risk patients 1
- Hold empagliflozin during acute illness 1
- Initial 24-hour urine volume increases by 341 mL on Day 1, decreasing to 135 mL by Day 5 2
- Absolute risk remains low, particularly at lower eGFR levels 1
Diabetic ketoacidosis (DKA):
- Can occur as euglycemic DKA with minimal blood glucose elevation 1
- Highest risk in insulin-requiring patients 1
- Mitigation strategies:
- Maintain at least low-dose insulin in insulin-dependent patients 1
- Institute sick day protocol (hold during acute illness/stressors) 1
- Monitor blood or urine ketones in very high-risk cases 1
- Educate patients on signs/symptoms for early recognition 1
- Discontinue immediately if ketoacidosis develops and seek emergency care 1
Hypoglycemia:
- Adjust background glucose-lowering agents (insulin, sulfonylureas) as appropriate 1
- Absolute risk is low, especially at lower eGFR 1
- Background therapy adjustment generally not required but may be prudent in select patients 1
Effects on Kidney Function
Initial eGFR decline:
- Reversible hemodynamic effect, not true kidney injury 1
- Does not require drug discontinuation 1
- Continue therapy even if eGFR falls below initiation threshold unless patient is intolerant or requires kidney replacement therapy 1
- After drug cessation, eGFR returns toward baseline (mean increase 0.56 mL/min/1.73 m²/week) 3
Protective effects:
- Reduces acute kidney injury risk 1
- Decreases urinary tract infection-related adverse reactions in CKD patients 6
Serious Adverse Events (Reduced by Empagliflozin)
In CKD patients, empagliflozin significantly reduces:
- All-cause mortality (48 fewer per 1000 in very high-risk patients) 7
- Kidney failure (58 fewer per 1000 in very high-risk patients) 7
- Cardiovascular mortality and hospitalizations 7
- All-cause hospitalizations (HR 0.86, including CV, renal, metabolic admissions) 8
Clinical Application by CKD Risk Strata
Very high-risk CKD patients: Strong recommendation for empagliflozin (high certainty evidence for mortality and kidney failure reduction) 7
High-risk CKD patients: Recommend empagliflozin (moderate certainty for mortality benefits) 7
Low-risk CKD patients: Suggest empagliflozin (weak recommendation, moderate certainty for small but important benefits) 7
eGFR considerations:
- Initiate at eGFR ≥20 mL/min/1.73 m² 1
- Glucose-lowering benefit decreases with worsening renal function 2
- Not effective in severe renal impairment, ESRD, or dialysis 2
- Continue if eGFR falls below 20 during treatment unless intolerant or on kidney replacement therapy 1
Key Monitoring Parameters
- Volume status at follow-up visits, particularly after initiation 1
- Glycemia reassessment, especially if on insulin or sulfonylureas 1
- eGFR monitoring with increasing frequency as eGFR falls below 60 mL/min/1.73 m² 1
- Ketone monitoring (blood or urine) in very high-risk patients 1
- Genital hygiene counseling and infection surveillance 1
Common Pitfalls to Avoid
- Do not discontinue empagliflozin due to initial eGFR decline—this is expected and protective 1, 3
- Do not stop when eGFR falls below initiation threshold during treatment 1
- Do not forget to maintain low-dose insulin in insulin-requiring patients to prevent DKA 1
- Do not overlook sick day protocols—hold during acute illness 1
- Do not assume lack of efficacy below eGFR 20—safety data exist down to eGFR 20, but not below 1
The renoprotective effects of empagliflozin are consistent regardless of baseline use of ACE inhibitors/ARBs, calcium channel blockers, diuretics, or NSAIDs 9. Benefits extend across diabetes status, eGFR levels, and albuminuria categories 7, 1.